Stock ScreenerStock IdeasZen Ratings + Top AnalystsStocks With a Zen Rating of A + Top Analyst consensus of Strong Buy + Large Upside in Target Price: May 21, 2025The 2 best sources of winning stocks is the Zen Ratings and our analysis of Top Analysts from Wall Street. Now we have combined them together in a best of both worlds approach to find stocks with the best upside potential.
Stock ScreenerStock IdeasZen Ratings + Top Analysts
Zen Rating: A
Upside/Downside: Large Upside
Top Analysts Consensus: Strong Buy
| Ticker | Company | Exchange | Industry | Zen Rating | Market Cap | Price | 1d % | EBITDA | P/E | D/E | Country | DD Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WIX | WIXCOM LTD | NASDAQ | Software - Infrastructure | A | $10.20B | $181.74 | 0.84% | $131.22M | 72.99x | -25.28 | Israel | 52 |
| ACIW | ACI WORLDWIDE INC | NASDAQ | Software - Infrastructure | A | $5.01B | $47.79 | -2.71% | $514.57M | 18.60x | 1.16 | United States | 47 |
| BGC | BGC GROUP INC | NASDAQ | Capital Markets | A | $4.75B | $9.74 | -2.89% | $365.61M | 34.79x | 3.88 | United States | 41 |
| SGHC | SUPER GROUP (SGHC) LTD | NYSE | Gambling | A | $4.25B | $8.44 | -0.71% | N/A | 28.42x | 0.69 | Guernsey | 46 |
| KMPR | KEMPER CORP | NYSE | Insurance - Property & Casualty | A | $4.11B | $64.26 | -0.53% | $486.60M | 11.90x | 3.28 | United States | 26 |
| PTCT | PTC THERAPEUTICS INC | NASDAQ | Biotechnology | A | $3.74B | $47.20 | 0.51% | $846.90M | 6.24x | -15.30 | United States | 35 |
| CPRX | CATALYST PHARMACEUTICALS INC | NASDAQ | Biotechnology | A | $3.01B | $24.68 | 0.20% | $296.55M | 14.96x | 0.14 | United States | 64 |
| AMRX | AMNEAL PHARMACEUTICALS INC | NASDAQ | Drug Manufacturers - Specialty & Generic | A | $2.33B | $7.42 | -1.07% | $503.18M | -185.50x | -26.56 | 17 | |
| FINV | FINVOLUTION GROUP | NYSE | Credit Services | A | $2.19B | $8.63 | -2.04% | $400.38M | 6.82x | 0.53 | China | 27 |
| ARDT | ARDENT HEALTH PARTNERS INC | NYSE | Medical Care Facilities | A | $2.16B | $15.13 | -0.13% | $500.18M | 9.01x | 2.85 | United States | 52 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | NASDAQ | Biotechnology | A | $2.16B | $10.33 | -0.39% | $47.59M | -39.73x | -2.06 | United States | 27 |
| PENG | PENGUIN SOLUTIONS INC | NASDAQ | Semiconductors | A | $1.01B | $18.85 | 0.59% | $91.31M | -110.88x | 1.99 | United States | 20 |
| YEXT | YEXT INC | NYSE | Software - Infrastructure | A | $867.69M | $6.86 | -0.29% | $169.00k | -31.18x | 2.98 | United States | 16 |
| EVER | EVERQUOTE INC | NASDAQ | Internet Content & Information | A | $855.10M | $23.65 | -1.42% | $46.12M | 21.90x | 0.55 | United States | 59 |
| NRDS | NERDWALLET INC | NASDAQ | Internet Content & Information | A | $818.89M | $10.99 | -2.40% | $51.20M | 28.18x | 0.28 | United States | 54 |
| QUAD | QUAD/GRAPHICS INC | NYSE | Specialty Business Services | A | $300.13M | $5.93 | 1.72% | $143.30M | -16.47x | 13.26 | United States | 12 |
| EXFY | EXPENSIFY INC | NASDAQ | Software - Application | A | $227.31M | $2.46 | 1.65% | $8.95M | -24.60x | 0.41 | United States | 20 |
| MAPS | WM TECHNOLOGY INC | NASDAQ | Software - Application | A | $172.90M | $1.12 | 4.67% | $24.98M | 14.00x | 1.24 | United States | 50 |
| RCMT | RCM TECHNOLOGIES INC | NASDAQ | Conglomerates | A | $167.91M | $22.72 | -1.86% | $25.25M | 12.84x | 2.50 | United States | 51 |
| BKTI | BK TECHNOLOGIES CORP | NYSEMKT | Communication Equipment | A | $166.96M | $45.45 | -1.92% | $11.28M | 16.47x | 0.73 | United States | 40 |
Upgrade to Premium to View More
Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More
Already have a premium account? Sign In
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.